Janssen Research & Development
3210 Merryfield Row
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
130 articles about Janssen Research & Development
MorphoSys AG Announces That Its Licensee Janssen R&D Has Reported New Data From Two Phase III Studies Of Guselkumab In Plaque Psoriasis
Janssen R&D Release: New Results From Second Phase III Study Show Significant Efficacy Of Guselkumab And Superiority Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis
Janssen R&D Release: Janssen Human Microbiome Institute Announces Multiple Collaborations To Accelerate The Translation Of Microbiome Science Into Health Solutions
Achillion Scores $15 Million Clinical Milestone From Janssen R&D for the Advancement of JNJ-4178 in Phase 2B
Janssen R&D Release: Late-breaking Phase 2 Ibrutinib Study In Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete Or Partial Response In Up To Two-Thirds Of Steroid Dependent Or Refractory Patients
Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Showed Consistent Clinical Benefit For Previously-Treated Patients With Multiple Myeloma
Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
MorphoSys AG Announces That Its Licensee Janssen R&D Has Submitted A Marketing Authorization Application For Guselkumab In Europe
MorphoSys AG Announces That Its Licensee Janssen R&D Has Submitted Biologics License Application For Guselkumab
Janssen R&D Release: New Phase 3 Monotherapy Study Of Sirukumab Versus Humira And Sirukumab Data In An Anti-TNF Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
Janssen R&D Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial
Janssen R&D Release: New Phase 3 Data Show SIMPONI ARIA (Golimumab) Significantly Improved Signs And Symptoms In Patients With Active Ankylosing Spondylitis
MorphoSys AG Announces That Its Licensee Janssen R&D Reports Positive Results From A Phase 3 Study Of Guselkumab In Plaque Psoriasis
Janssen R&D Release: New Phase 3 Data Show Significant Efficacy Versus Placebo And Superiority Of Guselkumab Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis
Janssen R&D To Present Data From Nine Abstracts On INVOKANA (Canagliflozin) At 2016 European Association For The Study Of Diabetes Annual Meeting
Janssen R&D Release: Esketamine Receives Breakthrough Therapy Designation from FDA for Major Depressive Disorder with Imminent Risk for Suicide
Janssen R&D And Johnson & Johnson To Provide Webcast Presentation On Phase 3 Data For DARZALEX (Daratumumab) And The Janssen Immuno-Oncology Strategy And Portfolio
Janssen R&D Release: Canagliflozin Phase 2 Study Demonstrates Glycemic Improvements In Adults With Type 1 Diabetes